ES2116066T3 - Ensayo de activacion del receptor quinasa. - Google Patents
Ensayo de activacion del receptor quinasa.Info
- Publication number
- ES2116066T3 ES2116066T3 ES95903133T ES95903133T ES2116066T3 ES 2116066 T3 ES2116066 T3 ES 2116066T3 ES 95903133 T ES95903133 T ES 95903133T ES 95903133 T ES95903133 T ES 95903133T ES 2116066 T3 ES2116066 T3 ES 2116066T3
- Authority
- ES
- Spain
- Prior art keywords
- receptor
- cells
- construct
- tyrosine kinase
- pct
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
SE INVENTA UN ENSAYO PARA MEDIR LA ACTIVACION (EJ.: AUTOFOSFORILACION) DE UN RECEPTOR DE TIROSINA QUINASA, DE INTERES. A) UNA PRIMERA FASE SOLIDA ESTA CUBIERTA CON UNA POBLACION, CONSIDERABLEMENTE HOMOGENEA, DE CELULAS, DE MANERA QUE ESTAS SE ADHIEREN A LA PRIMERA FASE SOLIDA. LAS CELULAS TIENEN, BIEN UN RECEPTOR DE TIROSINA QUINASA ENDOGENO O HAN SIDO TRANSFORMADAS CON UN RECEPTORTOR CON CODIFICACION DE ADN O "CONSTRUCCION DE RECEPTOR" Y EL ADN SE HA EXPRESADO DE MANERA QUE EL RECEPTOR O CONSTRUCCION DEL RECEPTOR SE PRESENTA EN LAS MEMBRANAS CELULARES DE LAS CELULAS. B) UN LIGANTE SE AÑADE ENTONCES A LA FASE SOLIDA CON LAS CELULAS ADHERIDAS, DE MANERA QUE EL RECEPTOR DE TIROSINA QUINASA ESTA EXPUESTO AL LIGANTE. C) DESPUES DE LA EXPOSICION AL LIGANTE, LAS CELULAS ADHERENTES SE SOLUBILIZAN, LIBERANDO ASI LISADO DE CELULA. D) UNA SEGUNDA FASE SOLIDA ESTA CUBIERTA CON UN AGENTE CAPTOR QUE QUE SE FIJA CONCRETAMENTE AL RECEPTOR DE TIROSINA QUINASA O, EN EL CASO DE UNA CONSTRUCCION DE RECEPTOR,AL POLIPEPTIDO INDICADOR. E) EL LISADO DE CELULA OBTENIDO EN EL PASO C) SE AÑADE A LOS POZOS QUE CONTIENEN EL AGENTE CAPTOR ADHERENTE, PARA CAPTAR EL RECEPTOR O CONSTRUCCION DE RECEPTOR EN LOS POZOS. F) DESPUES SE LLEVA A CABO UN PASO DE LAVADO, PARA ELIMINAR EL LISADO DE CELULA NO FIJADO, DEJANDO EL RECEPTOR CAPTURADO O CONSTRUCCION DE RECEPTOR. G) EL RECEPTOR CAPTURADO O CONSTRUCCION DE RECEPTOR SE EXPONE A UN ANTICUERPO ETIQUETADO DE ANTI-FOSFOTIROSINA, QUE DEFINE RESIDUOS FOSFORILADOS EN EL RECEPTOR DE TIROSINA QUINASA. H) SE MIDE LA FIJACION DEL ANTICUERPO DE ANTI-FOSFOTIROSINA AL RECEPTOR CAPTURADO O CONSTRUCCION DE RECEPTOR.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15756393A | 1993-11-23 | 1993-11-23 | |
US08/170,558 US6001621A (en) | 1993-11-23 | 1993-12-20 | Protein tyrosine kinases |
US28630594A | 1994-08-05 | 1994-08-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2116066T3 true ES2116066T3 (es) | 1998-07-01 |
Family
ID=27388031
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES95903133T Expired - Lifetime ES2116066T3 (es) | 1993-11-23 | 1994-11-18 | Ensayo de activacion del receptor quinasa. |
Country Status (12)
Country | Link |
---|---|
US (3) | US6025145A (es) |
EP (1) | EP0730740B1 (es) |
JP (1) | JP3442784B2 (es) |
AT (1) | ATE163231T1 (es) |
AU (1) | AU698975B2 (es) |
CA (1) | CA2175892C (es) |
DE (1) | DE69408541T2 (es) |
DK (1) | DK0730740T3 (es) |
ES (1) | ES2116066T3 (es) |
GR (1) | GR3026430T3 (es) |
HK (1) | HK1008440A1 (es) |
WO (1) | WO1995014930A1 (es) |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0711341A4 (en) * | 1993-07-29 | 2001-12-19 | Cor Therapeutics Inc | METHODS OF DETERMINING THE FUNCTION OF A RECEPTOR |
US6287784B1 (en) * | 1993-11-23 | 2001-09-11 | Genentech, Inc. | Kinase receptor activation assay |
US20050019325A1 (en) | 1996-01-08 | 2005-01-27 | Carter Paul J. | WSX receptor agonist antibodies |
US6541604B1 (en) | 1996-01-08 | 2003-04-01 | Genentech, Inc. | Leptin receptor having a WSX motif |
CA2241564C (en) | 1996-01-08 | 2013-09-03 | Genentech, Inc. | Wsx receptor and ligands |
US7074397B1 (en) | 1996-01-08 | 2006-07-11 | Genentech, Inc. | Method for enhancing proliferation or differentiation of a cell using ob protein |
AU727606B2 (en) | 1996-07-12 | 2000-12-14 | Genentech Inc. | Gamma-heregulin |
WO1998002540A1 (en) | 1996-07-12 | 1998-01-22 | Genentech, Inc. | Chimeric heteromultimer adhesins |
US6433154B1 (en) * | 1997-06-12 | 2002-08-13 | Bristol-Myers Squibb Company | Functional receptor/kinase chimera in yeast cells |
US6342220B1 (en) * | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
FR2776661B1 (fr) * | 1998-03-26 | 2002-04-05 | Centre Nat Rech Scient | Polypeptide immunoreactif du recepteur trka du ngf et utilisations |
US6253441B1 (en) * | 1999-04-16 | 2001-07-03 | General Electric Company | Fabrication of articles having a coating deposited through a mask |
GB9918057D0 (en) * | 1999-07-30 | 1999-10-06 | Univ Bristol | Therapeutic agents |
CA2378481A1 (en) * | 1999-08-06 | 2001-02-15 | Institut Pasteur | A method of effecting phosphorylation in eucaryotic cells using thiamine triphosphate |
US6406869B1 (en) * | 1999-10-22 | 2002-06-18 | Pharmacopeia, Inc. | Fluorescent capture assay for kinase activity employing anti-phosphotyrosine antibodies as capture and detection agents |
KR100823764B1 (ko) | 2000-06-22 | 2008-04-21 | 제넨테크, 인크. | 아고니스트 안티-티알케이-씨 모노클로날 항체 |
US7087726B2 (en) | 2001-02-22 | 2006-08-08 | Genentech, Inc. | Anti-interferon-α antibodies |
US6919173B2 (en) | 2001-09-10 | 2005-07-19 | Meso Scale Technologies, Llc. | Assay buffer, compositions containing the same, and methods of using the same |
US20050004008A1 (en) * | 2002-03-01 | 2005-01-06 | Frackelton A. Raymond | SHC proteins as therapeutic targets in proliferative diseases |
US7910314B2 (en) * | 2002-03-01 | 2011-03-22 | Roger Williams Hospital | Shc protein-related methods and compositions for the prognosis of breast, prostate and ovarian cancer |
HUP0600340A3 (en) | 2002-07-15 | 2011-06-28 | Genentech Inc | Methods for identifying tumors that are responsive to treatment with anti-erbb2 antibodies |
CA2500901A1 (en) * | 2002-10-04 | 2004-04-22 | Rinat Neuroscience Corp. | Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists |
WO2004032870A2 (en) * | 2002-10-08 | 2004-04-22 | Rinat Neuroscience Corp. | Methods for treating post-surgical pain by admisnistering a nerve growth factor antagonist and compositions containing the same |
UA80447C2 (en) | 2002-10-08 | 2007-09-25 | Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic | |
US7255860B2 (en) * | 2002-10-08 | 2007-08-14 | Rinat Neuroscience Corp. | Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody |
AU2003300397A1 (en) * | 2002-12-23 | 2004-07-22 | Rinat Neuroscience Corp. | Methods for treating taxol-induced sensory neuropathy |
US7569364B2 (en) | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
US9498530B2 (en) | 2002-12-24 | 2016-11-22 | Rinat Neuroscience Corp. | Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same |
PT2270048E (pt) * | 2002-12-24 | 2016-02-10 | Rinat Neuroscience Corp | Anticorpos anti-ngf e métodos de utilização dos mesmos |
US7655231B2 (en) | 2003-02-19 | 2010-02-02 | Pfizer Inc. | Methods for treating pain by administering a nerve growth factor antagonist and an NSAID |
PT1454992E (pt) * | 2003-03-07 | 2006-09-29 | Ist Naz Stud Cura Dei Tumori | Ensaio de quinase do linfoma anaplastico, reagentes e composicoes |
EP1606409B1 (en) | 2003-03-19 | 2010-09-01 | Biogen Idec MA Inc. | Nogo receptor binding protein |
WO2004084836A2 (en) * | 2003-03-20 | 2004-10-07 | Rinat Neuroscience Corp. | Methods for treating taxol-induced gut disorder |
US7579157B2 (en) * | 2003-07-10 | 2009-08-25 | Hoffmann-La Roche Inc. | Antibody selection method against IGF-IR |
US20050124965A1 (en) * | 2003-12-08 | 2005-06-09 | Becton, Dickinson And Company | Phosphatase inhibitor sample collection system |
HUE037549T2 (hu) | 2004-04-07 | 2018-09-28 | Rinat Neuroscience Corp | Eljárások csontrákfájdalom kezelésére idegi növekedési faktor antagonista antitest beadásával |
SV2006002143A (es) | 2004-06-16 | 2006-01-26 | Genentech Inc | Uso de un anticuerpo para el tratamiento del cancer resistente al platino |
JP4960865B2 (ja) | 2004-06-24 | 2012-06-27 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 脱髄に関連する状態の処置 |
KR20070038557A (ko) | 2004-07-22 | 2007-04-10 | 제넨테크, 인크. | Her2 항체 조성물 |
US7597884B2 (en) | 2004-08-09 | 2009-10-06 | Alios Biopharma, Inc. | Hyperglycosylated polypeptide variants and methods of use |
EP1662258A1 (en) * | 2004-11-25 | 2006-05-31 | Sirenade Pharmaceuticals AG | A substrate free in vitro protein kinase assay |
ZA200706017B (en) | 2005-01-21 | 2008-12-31 | Genentech Inc | Fixed dosing of her antibodies |
EP1850874B1 (en) | 2005-02-23 | 2013-10-16 | Genentech, Inc. | Extending time to disease progression or survival in ovarian cancer patients using pertuzumab |
US7189522B2 (en) * | 2005-03-11 | 2007-03-13 | Chembio Diagnostic Systems, Inc. | Dual path immunoassay device |
WO2006098804A2 (en) * | 2005-03-11 | 2006-09-21 | Chembio Diagnostic Systems, Inc. | Dual path immunoassay device |
AR054260A1 (es) * | 2005-04-26 | 2007-06-13 | Rinat Neuroscience Corp | Metodos de tratamiento de enfermedades de la neurona motora inferior y composiciones utilizadas en los mismos |
KR101245462B1 (ko) | 2005-07-08 | 2013-03-20 | 바이오겐 아이덱 엠에이 인코포레이티드 | Sp35 항체 및 그의 용도 |
JP2009516167A (ja) * | 2005-11-11 | 2009-04-16 | ロジャー・ウィリアムズ・ホスピタル | 癌処置における予測マーカーとしてのp66−shc |
JP5312039B2 (ja) | 2005-12-02 | 2013-10-09 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 脱髄の関与する状態の処置 |
US7846724B2 (en) | 2006-04-11 | 2010-12-07 | Hoffmann-La Roche Inc. | Method for selecting CHO cell for production of glycosylated antibodies |
US8128926B2 (en) | 2007-01-09 | 2012-03-06 | Biogen Idec Ma Inc. | Sp35 antibodies and uses thereof |
CN101980603A (zh) * | 2007-10-11 | 2011-02-23 | 比奥根艾迪克Ma公司 | LINGO-1和TrkB拮抗剂的用途 |
ATE539165T1 (de) | 2007-10-19 | 2012-01-15 | Becton Dickinson Co | Verfahren zum nachweis von beta-lactamase |
KR101658245B1 (ko) * | 2007-10-24 | 2016-09-22 | 바이오마커 스트레터지스 엘엘씨 | 개선된 세포 분석용 방법 및 장치 |
WO2009058908A2 (en) | 2007-10-29 | 2009-05-07 | Eisai R & D Management Co., Ltd. | Methods for prognosing the ability of a zearalenone analog compound to treat cancer |
EP2217697B1 (en) * | 2007-11-08 | 2015-06-10 | Biogen MA Inc. | Use of lingo-4 antagonists in the treatment of conditions involving demyelination |
JP5737944B2 (ja) | 2007-12-17 | 2015-06-17 | ファイザー・リミテッドPfizer Limited | 間質性膀胱炎の治療 |
SI2250279T1 (sl) | 2008-02-08 | 2016-10-28 | Medimmune, Llc | Protitelesa anti-IFNAR1 z zmanjšano afiniteto do FC liganda |
WO2009150623A1 (en) | 2008-06-13 | 2009-12-17 | Pfizer Inc | Treatment of chronic prostatitis |
EP2315779A2 (en) * | 2008-07-09 | 2011-05-04 | Biogen Idec MA Inc. | Compositions comprising antibodies to lingo or fragments thereof |
US20100022916A1 (en) | 2008-07-24 | 2010-01-28 | Javanbakhsh Esfandiari | Method and Apparatus for Collecting and Preparing Biological Samples for Testing |
WO2010047868A1 (en) * | 2008-08-18 | 2010-04-29 | Discoverx Corporation | Receptor tyrosine kinase assays |
SI2331090T1 (en) | 2008-09-19 | 2018-04-30 | Pfizer Inc. | Stable liquid antibody formulation |
WO2010047778A1 (en) | 2008-10-20 | 2010-04-29 | Becton Dickinson And Company | Compositions for the detection of intracellular bacterial targets and other intracellular microorganism targets |
WO2010146511A1 (en) | 2009-06-17 | 2010-12-23 | Pfizer Limited | Treatment of overactive bladder |
DK2493922T3 (en) | 2009-10-26 | 2017-04-24 | Hoffmann La Roche | Process for preparing a glycosylated immunoglobulin |
US8603835B2 (en) | 2011-02-10 | 2013-12-10 | Chembio Diagnostic Systems, Inc. | Reduced step dual path immunoassay device and method |
WO2013101771A2 (en) | 2011-12-30 | 2013-07-04 | Genentech, Inc. | Compositions and method for treating autoimmune diseases |
CN104470541A (zh) | 2012-05-14 | 2015-03-25 | 比奥根艾迪克Ma公司 | 用于治疗涉及运动神经元的疾患的lingo-2拮抗剂 |
WO2015050959A1 (en) | 2013-10-01 | 2015-04-09 | Yale University | Anti-kit antibodies and methods of use thereof |
CN106062560A (zh) | 2014-03-31 | 2016-10-26 | 默克专利股份公司 | 使用特异性抗体检测蛋白质修饰的方法 |
EP3578635B1 (en) | 2014-04-02 | 2021-11-03 | Chembio Diagnostic Systems, Inc. | Immunoassay utilizing trapping conjugate |
US20160116466A1 (en) | 2014-10-27 | 2016-04-28 | Chembio Diagnostic Systems, Inc. | Rapid Screening Assay for Qualitative Detection of Multiple Febrile Illnesses |
US10435467B2 (en) | 2015-01-08 | 2019-10-08 | Biogen Ma Inc. | LINGO-1 antagonists and uses for treatment of demyelinating disorders |
WO2022087274A1 (en) | 2020-10-21 | 2022-04-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibodies that neutralize type-i interferon (ifn) activity |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3311889A1 (de) * | 1983-03-31 | 1984-10-11 | Byk-Mallinckrodt Chemische Produkte Gmbh, 6057 Dietzenbach | Verfahren zur irreversiblen bindung von protein an polystyroloberflaechen unter erhaltung der biologischen aktivitaet, so erhaltene polystyroloberflaechen und ihre verwendung |
US4859609A (en) * | 1986-04-30 | 1989-08-22 | Genentech, Inc. | Novel receptors for efficient determination of ligands and their antagonists or agonists |
US4851341A (en) * | 1986-12-19 | 1989-07-25 | Immunex Corporation | Immunoaffinity purification system |
US5336603A (en) * | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
CA2128722A1 (en) * | 1992-01-22 | 1993-08-05 | William I. Wood | Novel protein tyrosine kinases |
DE69334053T2 (de) * | 1992-04-10 | 2007-01-04 | Dana-Farber Cancer Institute, Inc., Boston | Immunnachweis eines aktivierungszustandsspezifischen phosphoproteins |
AU6117294A (en) * | 1993-02-16 | 1994-09-14 | Auckland Uniservices Limited | Developmental tyrosine kinases and their ligands |
-
1994
- 1994-11-18 AU AU12108/95A patent/AU698975B2/en not_active Expired
- 1994-11-18 CA CA002175892A patent/CA2175892C/en not_active Expired - Lifetime
- 1994-11-18 DK DK95903133T patent/DK0730740T3/da active
- 1994-11-18 DE DE69408541T patent/DE69408541T2/de not_active Expired - Lifetime
- 1994-11-18 EP EP95903133A patent/EP0730740B1/en not_active Expired - Lifetime
- 1994-11-18 US US08/374,565 patent/US6025145A/en not_active Expired - Lifetime
- 1994-11-18 WO PCT/US1994/013329 patent/WO1995014930A1/en active IP Right Grant
- 1994-11-18 AT AT95903133T patent/ATE163231T1/de active
- 1994-11-18 JP JP51515095A patent/JP3442784B2/ja not_active Expired - Lifetime
- 1994-11-18 ES ES95903133T patent/ES2116066T3/es not_active Expired - Lifetime
-
1995
- 1995-05-15 US US08/441,104 patent/US5891650A/en not_active Expired - Lifetime
- 1995-05-15 US US08/440,816 patent/US5914237A/en not_active Expired - Lifetime
-
1998
- 1998-03-20 GR GR980400620T patent/GR3026430T3/el unknown
- 1998-07-17 HK HK98109252A patent/HK1008440A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
US5891650A (en) | 1999-04-06 |
CA2175892A1 (en) | 1995-06-01 |
CA2175892C (en) | 2000-03-07 |
ATE163231T1 (de) | 1998-02-15 |
DE69408541T2 (de) | 1998-08-06 |
GR3026430T3 (en) | 1998-06-30 |
EP0730740A1 (en) | 1996-09-11 |
US6025145A (en) | 2000-02-15 |
JP3442784B2 (ja) | 2003-09-02 |
DK0730740T3 (da) | 1998-09-28 |
JPH09505889A (ja) | 1997-06-10 |
AU1210895A (en) | 1995-06-13 |
AU698975B2 (en) | 1998-11-12 |
EP0730740B1 (en) | 1998-02-11 |
US5914237A (en) | 1999-06-22 |
DE69408541D1 (de) | 1998-03-19 |
WO1995014930A1 (en) | 1995-06-01 |
HK1008440A1 (en) | 1999-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2116066T3 (es) | Ensayo de activacion del receptor quinasa. | |
Wilce et al. | Physicochemical basis of amino acid hydrophobicity scales: evaluation of four new scales of amino acid hydrophobicity coefficients derived from RP-HPLC of peptides | |
ATE217344T1 (de) | Antigen bindende peptide (abtides) aus peptidbibliotheken | |
DE69334100D1 (de) | Elk ligand, ein cytokin | |
TR200002257T2 (tr) | Nükleer reseptör ligandları ve ligand bağlanma domainleri. | |
Gawler et al. | CaLB: a 43 amino acid calcium-dependent membrane/phospholipid binding domain in p120 Ras GTPase-activating protein. | |
CA2279881A1 (en) | A method of identifying modulators of cell surface membrane receptors useful in the treatment of disease | |
DE59914768D1 (de) | Entstörung von Immunoassays durch Substanzen, die aus den Framework-Regionen von Antikörpern abgeleitet sind | |
Ihara et al. | [3H] BQ-123, a highly specific and reversible radioligand for the endothelin ETA receptor subtype | |
CA2203246A1 (en) | Alk-7 (activin like kinase), a serine threonine kinase receptor | |
Suck et al. | Rapid method for arrayed investigation of IgE‐reactivity profiles using natural and recombinant allergens | |
WO2003019136A3 (en) | Methods for inhibiting angiogenesis | |
Chin et al. | The use of tributylphosphine and 4-(aminosulfonyl)-7-fluoro-2, 1, 3-benzoxadiazole in the study of protein sulfhydryls and disulfides | |
ATE207617T1 (de) | Verfahren zur untersuchung von hausstaub | |
Proniewicz et al. | Role of Phe‐D5 isotopically labeled analogues of bradykinin on elucidation of its adsorption mode on Ag, Au, and Cu electrodes. Surface‐enhanced Raman spectroscopy studies | |
Moss et al. | Solubility and posttranslational regulation of GP130/F11--a neuronal GPI-linked cell adhesion molecule enriched in the neuronal membrane skeleton. | |
DK0789844T3 (da) | Anvendelse af et BMP-proteinreceptor-kompleks til screening for aktive stoffer i knoglemetabolisme og celler, der er cotransficieret med en type II-BMP-receptor og en type I-BMP-receptor | |
CA2294969A1 (en) | Surfaces coated with streptavindin/avidin | |
WO1998045711A3 (en) | Assay for ligands to tyrosine kinase receptors | |
Dybkaer | Quantities and units for biological reference materials used with in vitro diagnostic measuring systems for antibodies | |
WO2003000732A3 (en) | Fragments of the retinoic acid-related orphan receptor (ror) comprising the lig and binding domain (lbd), crystal structure of the lbd of ror-beta and their applications | |
AU8857991A (en) | Polypeptides having human dopaminergic receptor activity, nucleic acids coding for said polypeptides and uses thereof for screening active substances on said polypeptides | |
Hogarth et al. | Characterization of FcR Ig-binding sites and epitope mapping | |
Kowalczyńska et al. | Semiquantitative evaluation of fibronectin adsorption on unmodified and sulfonated polystyrene, as related to cell adhesion | |
Metzger et al. | Signal transduction by FcεRI: Analysis of the early molecular events |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 730740 Country of ref document: ES |